Exelixis (EXEL) Net Cash Flow Growth (3y) (2013 - 2026)
Exelixis (EXEL) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Exelixis |
13.71 Bn |
12.93 Bn |
590.86 Mn |
-104.13% |
| Date | Value |
|---|
| Apr 3, 2026 |
-104.13% |
| Jan 2, 2026 |
37.68% |
| Oct 3, 2025 |
75.67% |
| Jul 4, 2025 |
42.11% |
| Apr 4, 2025 |
-34.96% |
| Jan 3, 2025 |
-37.97% |
| Sep 27, 2024 |
0.39% |
| Jun 28, 2024 |
-35.93% |
| Mar 29, 2024 |
-26.72% |
| Dec 29, 2023 |
-45.33% |
| Mar 31, 2023 |
-24.30% |
| Sep 30, 2022 |
32.12% |
| Jul 1, 2022 |
-188.49% |
| Apr 1, 2022 |
7.45% |
| Dec 31, 2021 |
54.14% |
| Oct 1, 2021 |
-17.45% |
| Jul 2, 2021 |
96.74% |
| Apr 2, 2021 |
29.15% |
| Jan 1, 2021 |
53.96% |
| Apr 3, 2020 |
42.35% |
